Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

9.05USD
5:59pm GMT
Change (% chg)

$-0.05 (-0.55%)
Prev Close
$9.10
Open
$9.15
Day's High
$9.15
Day's Low
$8.90
Volume
36,182
Avg. Vol
102,717
52-wk High
$14.25
52-wk Low
$6.25

Select another date:

Fri, Nov 10 2017

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

BRIEF-HitGen and Aduro Enter Research Collaboration

* Entered into a multi-target multi-year collaboration with Aduro Biotech Inc

BRIEF-Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders‍​

* Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders‍​ - sec filing Source text - http://bit.ly/2v0rE5d Further company coverage:

BRIEF-Aduro Biotech files for mixed shelf of upto $300 mln

* Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing Source text - http://bit.ly/2w7SKYi Further company coverage:

BRIEF-Aduro Biotech Q2 loss per share $0.27

* Aduro Biotech reports second quarter 2017 financial results

BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck

* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody​

BRIEF-Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda

* Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda® (pembrolizumab) for the treatment of patients with previously treated malignant pleural mesothelioma Source text for Eikon: Further company coverage:

Select another date: